Do Finnish women using hormone replacement therapy need more information about risks

Pharmacy World and Science

Volumn 29, Issue 6, 2007, Pages 635-640

  Tiihonen, Miia J ^a   Heikkinen, Anna Mari ^b   Ahonen, Riitta S ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Counselling; Finland; Hormone replacement therapy; HRT; Medicine information

Indexed keywords

ESTROGEN; GESTAGEN; TIBOLONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEAR; FEMALE; FINLAND; HEALTH CARE PERSONNEL; HEALTH SURVEY; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MASS MEDIUM; MEDICAL INFORMATION; PATIENT INFORMATION; PERCEPTION; PHARMACIST; PHYSICIAN; PUBLICATION; QUESTIONNAIRE; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT; WOMEN'S HEALTH;

ADULT; AGED; COUNSELING; ESTROGEN REPLACEMENT THERAPY; FEAR; FEMALE; FINLAND; HUMANS; INFORMATION DISSEMINATION; MIDDLE AGED; RISK;

EID: 35348830405     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-007-9115-1     Document Type: Article

References (23)

1. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 280:605-613
2. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al (2002) Writing group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
3. Beral V (2003) Million Women Study Collaborators. Breat cancer and hormone replacement therapy in the Million Women Study. Lancet 362:419-427
4. USPSTF (2003) Postmenopausal hormone replacement therapy for the primary prevention of chronic condition. Recommendations and rationale. U.S. Preventive Services Task Force. Am Fam Physician 67:358-364
5. The European Medicines Agency (2003) Public Statement on recent Publications regarding Hormone Replacement Therapy. EMEA [cited 2003 Dec 15]. Available from: http://www.emea.eu.int/pdfs/human/press/pus/3306503en.pdf
6. National Agency for Medicines, Social Insurance Institution. Finnish statistics on medicines, Helsinki: Edita Prima Oy, 1987-2005. ISSN 0786-2180
7. National Agency for Medicines, Social Insurance Institution (2006) Finnish statistics on medicines. Drug consumption January-June 2006. National Agency of Medicines; [cited 2006 Nov 8]. Available from: http://www.nam.fi/ kulutus/kv_laakekulutus.htm
8. Apoteket. Läkemedelsutvecklingen - försäljingvolym januari-juni 2003. Apoteket; 2004 [cited 2004 January 8]. Available from: http://www.apoteket.se
9. Hersh AL, Stefanick ML, Stafford RS (2004) National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291:47-53
10. Lawton B, Rose S, McLeod D, Dowell A (2003) Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users. Br Med J 327:845-846
11. Usher C, Teeling M, Bennet K, Feely J (2006) Effect of clinical trial publicity on HRT prescribing in Ireland. Eur J Clin Pharmacol 24:1-4
12. Levens E, Williams RS (2004) Current opinions and understandings of menopausal women about hormone replacement therapy (HRT)- the University of Florida experience. Am J Obstet Gynecol 191:641-647
13. Walter FM, Emery JD, Rogers M, Britten N (2004) Women's views of optimal risk communication and decision making in general practice consultations about the menopause and hormone replacement therapy. Patient Educ Couns 53:121-128
14. Leppänen H-M, Ehkäisypillereiden käytön edut-ja haitat - tutkimus e-pillereiden käyttäjien kokemuksista [The benefits and adverse reactions of oral contraceptive users - users' experiences]. Master's thesis. Department of Social Pharmacy: University of Kuopio, 2001
15. Sihvo S, Ahonen R, Mikander H, Hemminki E (2000) Self-medication with vaginal antifungal drugs: physicians' experiences and women's utilization patterns. Fam Pract 17:145-149
16. Veerus P, Hovi S-L, Fischer K, Rahu M, Hakama M, Hemminki E (2006) Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas 55:162-173
17. Vainio KK, Airaksinen MS, Hyykky TT, Enlund KH (2002) Effect of therapeutic class on counselling in community pharmacies. Ann Pharmacother 36:781-786
18. Herxheimer A (1989) Regulatory Approaches. The consumer viewpoint. In: Bogaert M, v.d. Stichele R, Kaufman J-M, Levebvre R (eds). Patient package inserts as a source of drug information. Amsterdam-New York-London: Excerpta Medica, pp 73-76. ISBN 0-444-81079-X
19. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K (2004) Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 140:184-188
20. Vihtamaki T, Savilahti R, Tuimala R (1999) Why do postmenopausal women discontinue hormone replacement therapy? Maturitas 33:99-105
21. Oddens BJ, Boulet MJ (1997) Hormone replacement therapy among Danish women aged 45-65 years: prevalence, determinants, and compliance. Obstet Gynecol 90:269-277
22. Sihvo S, Hemminki E (1997) Self-medication of dyspepsia: how appropriate is it? Scand J Gastroenterol 32:855-861
23. Luoto R, Hemminki E, Kaaja R, Lindbohm M-L (2004) Hormonikorvaushoito ja kohdunpoisto [Hormone replacement therapy and hysterectomy]. In: Koponen P, Luoto R (eds). Lisääntymisterveys Suomessa [Reproductive health in Finland]. Terveys 2000-tutkimus. [The Health 2000 survey]. Helsinki: National Public Health Institute, pp 62-68. ISBN 951-740-422-0